Home > Neurology > MS Virtual 2020 > Treatment Strategies and Results > TERIKIDS trial extension of teriflunomide in paediatric MS

TERIKIDS trial extension of teriflunomide in paediatric MS


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
Trial
Phase 3, TERIKIDS
During the combined double-blind and open-label periods in the TERIKIDS-trial, continuous teriflunomide numerically lowered clinical relapses and the risk of 24-week sustained disability progression compared with delayed initiation of teriflunomide after placebo [1]. Teriflunomide was well tolerated and had a manageable safety profile. TERIKIDS (NCT02201108) is a 2-year, multicentre, multinational, randomised, double-blind, placebo-controlled, parallel-group phase 3 study of teriflunomide in children and adolescents of 10-17 years at baseline with relapsing MS. It is followed by a 96-week open-label period, of which interim results were shared. All participants in the open-label period (n=152) received teriflunomide at a dose based on body weight, equivalent to 14 mg in adults. The primary endpoint in the double-blind period, median time to first ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on